Heffernan Ann E, Katz Erin M, Sun Yiwen, Rendahl Aaron K, Conzemius Michael G
University of Minnesota Veterinary Medical Center, St Paul, Minnesota.
University of Minnesota School of Statistics, Minneapolis, Minnesota.
Vet Surg. 2018 May;47(4):516-523. doi: 10.1111/vsu.12792. Epub 2018 Apr 9.
To determine the efficacy of oral extended-release hydrocodone compared with oral firocoxib for analgesia following tibial plateau leveling osteotomy surgery in dogs in a hospital setting.
Prospective, randomized, blinded, clinical trial.
Thirty-six client-owned dogs weighing 25-43 kg with unilateral hindlimb lameness and cranial cruciate ligament rupture.
Dogs were assigned to 1 of 2 groups (n = 18/group). Group 1 received hydrocodone 3 mg/kg orally every 24 hours, and group 2 received firocoxib 5 mg/kg orally every 24 hours. Both hydrocodone and firocoxib (according to group assignment) were provided as preemptive analgesia 10 hours before induction to anesthesia and then every 24 hours for the remainder of the study period The level of analgesia was compared between treatments on the basis of a modified Glasgow Composite Pain Score (mGCPS) in each dog, the number of dogs requiring rescue analgesia (hydromorphone 0.05 mg/kg subcutaneously), pressure platform stance data, and number of adverse events.
Nine of 18 dogs that received hydrocodone and 2/18 dogs that received firocoxib had an mGCPS ≥6 (P = .02). Two dogs had an mGCPS ≥6 three times, and 1 had an mGCPS ≥6 two times; all 3 of these dogs were in the hydrocodone group. Average postoperative peak pressure placed on the affected limb was lower in dogs that received hydrocodone (P = .01). Regurgitation and decreased appetite were more common in the dogs that received hydrocodone.
Dogs that were treated with hydrocodone exhibited higher pain scores and lower limb function than dogs treated with firocoxib under the conditions of our study.
Our results do not provide evidence to justify the administration of extended-release hydrocodone at 3 mg/kg orally every 24 hours rather than firocoxib at 5 mg/kg orally every 24 hours in dogs undergoing tibial plateau leveling osteotomy.
在医院环境中，确定口服缓释氢可酮与口服非罗考昔相比，对犬胫骨平台平整截骨术后镇痛的疗效。
前瞻性、随机、双盲临床试验。
36只客户拥有的犬，体重25 - 43千克，单侧后肢跛行且颅交叉韧带断裂。
将犬分为2组中的1组（每组n = 18只）。第1组每24小时口服3毫克/千克氢可酮，第2组每24小时口服5毫克/千克非罗考昔。在诱导麻醉前10小时，氢可酮和非罗考昔（根据分组）均作为超前镇痛用药，然后在研究期剩余时间内每24小时用药一次。根据每只犬的改良格拉斯哥综合疼痛评分（mGCPS）、需要补救镇痛（皮下注射0.05毫克/千克氢吗啡酮）的犬数量、压力平台站立数据以及不良事件数量，比较两种治疗方法的镇痛水平。
接受氢可酮治疗的18只犬中有9只、接受非罗考昔治疗的18只犬中有2只mGCPS≥6（P = 0.02）。2只犬mGCPS≥6出现过3次，1只犬mGCPS≥6出现过2次；这3只犬均在氢可酮组。接受氢可酮治疗的犬术后患侧肢体平均峰值压力较低（P = 0.01）。反流和食欲下降在接受氢可酮治疗的犬中更常见。
在我们的研究条件下，接受氢可酮治疗的犬比接受非罗考昔治疗的犬表现出更高的疼痛评分和更低的肢体功能。
我们的结果没有提供证据支持在接受胫骨平台平整截骨术的犬中，每24小时口服3毫克/千克缓释氢可酮而非每24小时口服5毫克/千克非罗考昔的给药方式。
